News

In this second of a two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says he is in favor of extending CMS waivers that made telehealth visits reimbursable and easy for patients and providers.

The investigational monoclonal antibody therapy bamlanivimab treats mild-to-moderate COVID-19 in adult and pediatric patients.

While Pfizer and BioNTech’s first interim analysis demonstrates the efficacy of their SARS-CoV-2 vaccine candidate, some questions remain.

So far, hospitals and other healthcare providers have received approximately $125 billion of the $175 billion allocated to the federal Provider Relief Fund to cover costs related to coronavirus care. This injection of resources has helped providers manage the costs related to the coronavirus, but it has also raised questions about the requirements for accepting and spending the funds.

Earlier treatment of multiple sclerosis with disease-modifying therapy reduced the chances of a sharp decrease in income, according to Swedish researchers.

Vivek Murthy, M.D., MBA, former surgeon general, David Kessler, M.D., former FDA commissioner, and Marcella Nunez-Smith, M.D., M.H.S., an associate professor at Yale Medical School are the co-chairs

University of Vermont researchers say their data show there are alternative approaches to using gadolinium-based contrast agents in follow-up MRIs of patients with multiple sclerosis.

Some safe predictions for healthcare under the Biden administration: More deference to public health officials on COVID-19 and efforts to create a public option and have Medicare negotiate drug prices.

A Phase 3 trial is in the works in the U.S. for Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS).

In this first of two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says the Boston-based telehealth company typically white labels its software to a client’s brand.

The U.S. post-acute care market is growing at 4% and is expected to be $470B in value by 2026, spanning across various post-acute settings.

A survey by Luma Health shows that 52% of patients are comfortable or very comfortable with telehealth. A quarter of providers see a risk of their organizations going out of business.

While ongoing stress from COVID-19 has had an effect on many people's mental health, contracting the virus may have much more of an impact on the brain.

At a time like this, it is important for providers and health systems to establish an OBGYN communication strategy to ensure existing and prospective patients are aware of the precautions their obstetricians are taking to safely deliver babies and conduct routine appointments for those who are, or plan to become, pregnant.

RAND study puts some numbers to telehealth surge but also shows evidence of disparities along income, racial/ethnic lines.

In this episode, Briana Contreras of MHE spoke with Aaron Fulner, Senior Director of Edifecs, a global health IT company. The two had a conversation about open enrollment and how private and public insurance markets have been preparing or are now experiencing an influx of new enrollees due to approximately 12 million people losing access to employer coverage from job losses since February.

As hospitals and health systems struggle to regain revenue, they will find themselves competing aggressively to attract and retain a smaller pool of patients. It will require doubling down on the patient experience, but will create a larger boost of healthcare consumerization, overall.

While physical and mental effects of Autosomal Dominant Polycystic Kidney Disease are top of mind for those personally impacted, as well as for nephrologists, the financial implications associated with this condition are often overlooked despite the fact that research has confirmed the economic burden of the disease increases over time for both the patient and the healthcare system.

Recalls of metformin products due to higher levels of the probable carcinogenic ingredient N-Nitrosodimethylamine (NDMA) than allowed continue.

Forty-three percent of new cases in nursing homes are coming from midwest states.

Trump jokes about potentially firing NIAID Director Anthony S. Fauci.

Time to make your prediction even if we won't know the answer for awhile.

What do the two presidential candidates have right in healthcare policy? Where do they both go wrong? And what will it take for payment reform to take off? Michael Abrams of Numerof discusses what comes after Election Day.

Open enrollment has started and the median premium increase is 1.1%, according to the Kaiser Family Foundation.

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

Research from a Doximity survey shows physician wages have grown by only 1.5% amid COVID-19 pandemic, and gender pay gap among doctors persists at 28%.

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

With the uptick in claims denials, which have increased sharply due to CARES-related provisions, the onus is on providers to directly address a problem that’s only going to get worse as we continue to work our way through the COVID-19 pandemic. Recommended is a 4-pronged approach for providers to address this.

Falls are the current leading cause of injuries for older Americans, and many of them result in permanent disability and fatalities. The risk of falling for older adults doubles if they have impaired vision from a degenerative eye disease like diabetic retinopathy.

Here's what healthcare executives can expect depending who wins next week's election.